FDA Approves Supplemental Application for TASCENSO ODT
The FDA has approved a supplemental application for TASCENSO ODT, containing Fingolimod Lauryl Sulfate.
Asset / Drug
Drug and asset intelligence for CYCLE with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.